DVAX Dynavax Technologies Corporation

3.99
+0.08  (+2%)
Previous Close 3.91
Open 3.94
Price To Book 24.94
Market Cap 259,967,369
Shares 65,154,729
Volume 1,310,635
Short Ratio
Av. Daily Volume 1,739,175

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced May 23, 2019 that it will discontinue investment in this program.
SD-101 + Pembrolizumab
Melanoma and head and neck squamous cell carcinoma (HNSCC)
CRL February 25, 2013 and November 14, 2016. Advisory Committee Meeting July 28, 2017 voted 21 -1 in favor of recommending approval. Final approval announced November 9, 2017.
HEPLISAV-B
Hepatitis B
Phase 2a trial did not meet primary endpoint - November 29, 2018.
AZD1419
Asthma
Announced May 23, 2019 that it will discontinue investment in this program.
DV281
Non-small Cell Lung Cancer (NSCLC)
Phase 1 commencement of enrolment announced May 2, 2019.
HEPLISAV-B
End Stage Renal Disease on Dialysis

Latest News

  1. Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors
  2. Edited Transcript of DVAX earnings conference call or presentation 7-Aug-19 8:30pm GMT
  3. Dynavax Technologies Corp (DVAX) Q2 2019 Earnings Call Transcript
  4. Dynavax Technologies Announces Pricing of $70.1 Million Public Offering of Common Stock, Non Voting Preferred Stock and Warrants to Purchase Common Stock
  5. Dynavax Technologies (DVAX) Reports Q2 Loss, Tops Revenue Estimates
  6. Dynavax Technologies Announces Proposed Public Offering of Common Stock, Non-Voting Preferred Stock and Warrants to Purchase Common Stock
  7. Dynavax Announces Second Quarter 2019 Financial Results
  8. Dynavax Technologies to Report Second Quarter 2019 Financial Results and Host Conference Call on August 7
  9. Are These 2 Beaten-Down Biotech Stocks Worth Buying?
  10. Here's Why Dynavax Technologies Fell Again Today
  11. Dynavax Technologies Sees Hammer Chart Pattern: Time to Buy?
  12. 3 Biotech Stocks That Could Double Your Money
  13. Dynavax: Last Chance to Make Good
  14. Why Dynavax Technologies' Stock Tanked in June
  15. Here’s What Hedge Funds Think About Dynavax Technologies Corporation (DVAX)
  16. Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference  
  17. Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting
  18. Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting
  19. Dynavax (DVAX) to Cut Jobs and Focus on Vaccine Business
  20. The Week Ahead In Biotech: ASCO Presentations In The Spotlight